Dr. Paulson Discusses Acquired Resistance to Immunotherapy

Kelly Paulson, MD
Published: Friday, Nov 17, 2017



Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

One of the biggest challenges in immunotherapy is resistance to treatment, says Paulson. Investigators are currently trying to develop next-generation immunotherapies to treat patients who initially responded to immunotherapy, but then recurred.
 


Kelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

One of the biggest challenges in immunotherapy is resistance to treatment, says Paulson. Investigators are currently trying to develop next-generation immunotherapies to treat patients who initially responded to immunotherapy, but then recurred.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x